RxDoctor Payments Data

David McElwain, MD

Psychiatry · Tulsa, OKNPI 1003928334

Payments from drug & device makers

$160in general payments, 2019–2025

Across 10 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$28
  • Vanda Pharmaceuticals Inc.$26
  • Sunovion Pharmaceuticals Inc.$24
  • Teva Pharmaceuticals USA, Inc.$17
  • Indivior Inc.$16
  • Otsuka America Pharmaceutical, Inc.$15
  • plus $34 from 3 others

What the payments were for

  • Food & beverage$160100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$160 in reported general payments places this provider in the 40th percentile of 328 psychiatry providers in Oklahoma.

See all psychiatry providers in Oklahoma

Medicare billing

Part B allowed, 2024
$15,645
Medicare patients
119
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate146$495,508
Invega TrinzaPaliperidone Palmitate30$313,355
Invega HafyeraPaliperidone Palmitate11$190,563
Abilify MaintenaAripiprazole57$161,803
VraylarCariprazine Hcl41$60,256
AristadaAripiprazole Lauroxil15$52,725
Chlorpromazine Hcl72$29,635
Clozapine114$12,867
BelsomraSuvorexant26$11,070
Haloperidol139$8,632
Aripiprazole318$7,230
TrintellixVortioxetine Hydrobromide15$7,006
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine150$5,480
Fluphenazine Hcl35$5,345
Olanzapine359$5,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$28$808,863176 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$15$161,80357 claims
AbbVieVraylar$12$60,25641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 328 psychiatry providers in Oklahoma.

Other psychiatry in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →